In adult patients receiving continuous renal replacement therapy (CRRT), how long can the filter remain in place before it should be changed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CRRT Filter Duration and Replacement

In adult patients receiving CRRT, filters should be changed routinely at 48-72 hours to maintain adequate solute clearance, though filters may function acceptably for up to 72 hours with proper anticoagulation. 1

Evidence-Based Filter Lifespan Recommendations

Routine Replacement Timing

  • Filters should be changed at 48-72 hours on a routine basis to prevent progressive decline in delivered dose that occurs over time 1
  • Without anticoagulation, circuit life may be less than 24 hours, making it difficult to deliver adequate renal support 2
  • Failure before 8 hours is associated with inadequate renal support and should trigger clinical review of circuit setup and catheter function 3

Filter Performance Over Time

  • Prescribed clearance progressively overestimates actually delivered clearance as filter function declines, with the difference increasing over time 1
  • Small molecule (urea, creatinine) clearance remains relatively stable for the first 48 hours, but middle molecule clearance (beta-2 microglobulin) begins to decline significantly by 72 hours 4
  • The mean filter lifespan across studies is approximately 37.7 hours (SD 17.6) when using standard anticoagulation protocols 1

Factors That Extend Filter Life

Anticoagulation Strategy (Most Important)

  • Regional citrate anticoagulation provides the longest filter life (median 48 hours, IQR 20.3-75.0 hours) compared to heparin (median 5.9 hours, IQR 8.5-27.0 hours) or no anticoagulation (median 17.5 hours, IQR 9.5-32 hours) 5
  • Citrate anticoagulation also delivers higher actual dialysis doses due to improved filter efficacy 5
  • CVVHD (dialysis mode) provides significantly longer filter lifespan (median 37 hours, IQR 19.5-72.5) compared to CVVH (hemofiltration mode) (median 19 hours, IQR 12.5-28) 4

Blood Flow Rate

  • Higher blood flow rates predict longer filter lifespan in multivariable analyses (p=0.03 for all filters, p=0.04 for non-electively ceased filters) 6
  • Optimizing blood flow through proper catheter selection and positioning is critical for filter longevity 6

Patient Factors

  • Lower platelet counts are associated with longer filter life (p=0.003 for all filters, p<0.001 for non-electively ceased filters), likely reflecting reduced thrombotic tendency 6
  • Vascular catheter design may influence filter lifespan, though the specific optimal design remains unclear 6

Monitoring Filter Function

Clinical Indicators for Early Replacement

  • Rising transmembrane pressure is significantly correlated with declining filter performance (Spearman's rho 0.44, p<0.001) 1
  • Document actual filter life (elapsed hours) at the bedside as a quality measure 3
  • Monitor effluent urea nitrogen/blood urea nitrogen ratios to assess filter efficacy 5

When to Replace Before Scheduled Time

  • Replace immediately if transmembrane pressure rises significantly above baseline 1
  • Replace if circuit clots or blood flow becomes inadequate despite troubleshooting 3
  • Replace if filter life is consistently <8 hours, as this indicates inadequate therapy delivery 3

Common Pitfalls to Avoid

  • Do not rely solely on prescribed dose as a measure of adequate therapy—prescribed clearance overestimates delivered clearance by 9.3% on average (95% CI: -4.4% to 32.3%), with the gap widening over time 1
  • Do not extend filters beyond 72 hours routinely, as solute clearance efficiency declines progressively even if the circuit remains patent 1, 4
  • Do not assume heparin provides adequate anticoagulation—it results in significantly shorter filter life compared to citrate without reducing bleeding complications 5
  • Avoid subclavian vein access when possible due to thrombosis and stenosis risk, which can compromise catheter function and filter life 2, 7

References

Research

Actually delivered dose of continuous renal replacement therapy is underestimated in hemofiltration.

ASAIO journal (American Society for Artificial Internal Organs : 1992), 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD).

Hemodialysis international. International Symposium on Home Hemodialysis, 2014

Research

Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables.

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2014

Guideline

CRRT Orders: A Comprehensive Guide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Are adsorption filters for Continuous Renal Replacement Therapy (CRRT) readily available and easily accessible?
What is the difference between Continuous Veno-Venous Haemofiltration (CVVH), Continuous Veno-Venous Haemodialysis (CVVHD), and Continuous Veno-Venous Haemodiafiltration (CVVHDF)?
What are the differences between Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), Continuous Veno-Venous Hemodiafiltration (CVVHDF), and Continuous Veno-Venous Hemodialysis with Hemofiltration (CVVHDH)?
How can filter life be increased on Continuous Renal Replacement Therapy (CRRT)?
What is the optimal molecule size for removal during Sustained Continuous Renal Replacement Therapy (SCRRT)?
What are the National Comprehensive Cancer Network (NCCN) guidelines for hepatic metastasectomy in a 68‑year‑old man who had a stage IB sigmoid adenocarcinoma resected with open sigmoidectomy and primary anastomosis one year ago and now has an ovoid hypo‑enhancing lesion in liver segments 5‑6 consistent with possible colorectal liver metastasis?
I’m a healthy young adult with an incomplete right bundle‑branch block on a 12‑lead ECG; what is its significance and do I need any further testing or treatment?
What are the biochemical abnormalities in polycystic ovary syndrome (PCOS) and what is the first‑line management?
How should I evaluate and manage anemia in a pregnant patient?
In a 37‑year‑old woman presenting with dizziness, visual changes, palpitations and nausea, when should I suspect missed skull or cervical spine fractures and what imaging is indicated?
What is the recommended postoperative fluid management (type, rate, monitoring, and transition to oral intake) for an adult surgical patient, including adjustments for cardiac or renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.